OptimizeRx (OPRX) Stock Forecast, Price Target & Predictions
OPRX Stock Forecast
OptimizeRx stock forecast is as follows: an average price target of $15.00 (represents a 205.50% upside from OPRX’s last price of $4.91) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
OPRX Price Target
The average price target for OptimizeRx (OPRX) is $15.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 205.50% upside from OPRX's last price of $4.91.
OPRX Analyst Ratings
According to 4 Wall Street analysts, OptimizeRx's rating consensus is 'Buy'. The analyst rating breakdown for OPRX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
OptimizeRx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | Constantine Davides | JMP Securities | $15.00 | $11.17 | 34.29% | 205.50% |
The latest OptimizeRx stock forecast, released on Apr 04, 2024 by Constantine Davides from JMP Securities, set a price target of $15.00, which represents a 34.29% increase from the stock price at the time of the forecast ($11.17), and a 205.50% increase from OPRX last price ($4.91).
OptimizeRx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $15.00 |
| Last Closing Price | $4.91 | $4.91 | $4.91 |
| Upside/Downside | -100.00% | -100.00% | 205.50% |
In the current month, the average price target of OptimizeRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to OptimizeRx's last price of $4.91. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 14, 2024 | Lake Street | Buy | Buy | Hold |
| Aug 12, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jun 21, 2024 | Stifel Nicolaus | Market Outperform | Market Outperform | Hold |
| May 15, 2024 | Stifel Nicolaus | Market Outperform | Market Outperform | Hold |
| May 15, 2024 | RBC Capital | Underperform | Underperform | Hold |
| May 15, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Apr 04, 2024 | JMP Securities | Market Outperform | Outperform | Initialise |
| Apr 04, 2024 | JMP Securities | Market Outperform | Initialise | |
| Apr 01, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 10, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Jul 15, 2022 | SVB Leerink | Buy | Initialise |
OptimizeRx's last stock rating was published by Lake Street on Nov 14, 2024. The company gave OPRX a "Buy" rating, the same as its previous rate.
OptimizeRx Financial Forecast
OptimizeRx Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Dec 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $16.33M | $13.82M | $13.00M | $19.65M | $15.09M | $13.98M | $13.73M | $20.31M | $16.12M | $13.63M | $11.23M | $16.43M | $10.52M | $8.78M | $7.58M | $7.38M | $5.00M | $7.01M | $5.21M | $4.11M | $4.01M |
| Avg Forecast | $33.61M | $24.52M | $21.66M | $21.00M | $29.54M | $24.99M | $20.16M | $18.13M | $27.92M | $15.14M | $14.80M | $12.35M | $21.77M | $14.92M | $17.06M | $13.55M | $20.16M | $15.14M | $12.45M | $10.47M | $16.01M | $9.77M | $7.97M | $7.03M | $7.57M | $7.18M | $6.69M | $5.10M | $8.22M | $4.01M |
| High Forecast | $34.50M | $25.17M | $22.23M | $21.38M | $30.26M | $25.05M | $20.16M | $18.13M | $28.16M | $15.20M | $15.20M | $12.68M | $22.35M | $14.92M | $17.06M | $13.55M | $20.16M | $15.14M | $12.45M | $10.47M | $16.01M | $9.77M | $7.97M | $7.03M | $7.57M | $7.18M | $6.69M | $5.10M | $9.86M | $4.81M |
| Low Forecast | $32.66M | $23.83M | $21.05M | $20.63M | $28.42M | $24.93M | $20.16M | $18.13M | $27.66M | $15.08M | $14.39M | $12.01M | $21.15M | $14.92M | $17.06M | $13.55M | $20.16M | $15.14M | $12.45M | $10.47M | $16.01M | $9.77M | $7.97M | $7.03M | $7.57M | $7.18M | $6.69M | $5.10M | $6.58M | $3.21M |
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 0.93% | 1.05% | 0.90% | 1.01% | 0.82% | 1.01% | 1.01% | 1.07% | 1.09% | 1.07% | 1.03% | 1.08% | 1.10% | 1.08% | 0.98% | 0.70% | 1.05% | 1.02% | 0.50% | 1.00% |
OptimizeRx's average Quarter revenue forecast for Dec 23 based on 3 analysts is $27.92M, with a low forecast of $27.66M, and a high forecast of $28.16M. OPRX's average Quarter revenue forecast represents a 70.94% increase compared to the company's last Quarter revenue of $16.33M (Sep 23).
OptimizeRx EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Dec 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-3.09M | $-4.42M | $-6.60M | $-407.80K | $-3.24M | $-3.33M | $-3.29M | $1.01M | $565.93K | $880.06K | $-111.20K | $1.76M | $240.53K | $-556.67K | $-1.68M | $-2.45M | $-1.25M | $642.19K | $196.83K | $-134.71K | $-261.93K |
| Avg Forecast | $-3.52M | $-2.57M | $-2.27M | $-2.20M | $-3.10M | $-2.62M | $-2.11M | $-5.26M | $-2.93M | $-1.59M | $-1.55M | $-4.16M | $1.06M | $-1.10M | $-1.26M | $-3.29M | $-1.49M | $-1.12M | $-917.80K | $-111.20K | $-1.18M | $-720.25K | $-587.88K | $-1.85M | $-557.81K | $-529.57K | $-493.16K | $620.01K | $-181.85K | $-261.93K |
| High Forecast | $-3.42M | $-2.50M | $-2.21M | $-2.16M | $-2.98M | $-2.61M | $-2.11M | $-4.21M | $-2.90M | $-1.58M | $-1.51M | $-3.33M | $1.27M | $-1.10M | $-1.26M | $-2.63M | $-1.49M | $-1.12M | $-917.80K | $-88.96K | $-1.18M | $-720.25K | $-587.88K | $-1.48M | $-557.81K | $-529.57K | $-493.16K | $744.02K | $-145.48K | $-209.54K |
| Low Forecast | $-3.62M | $-2.64M | $-2.33M | $-2.24M | $-3.17M | $-2.63M | $-2.11M | $-6.32M | $-2.95M | $-1.59M | $-1.59M | $-4.99M | $845.31K | $-1.10M | $-1.26M | $-3.95M | $-1.49M | $-1.12M | $-917.80K | $-133.44K | $-1.18M | $-720.25K | $-587.88K | $-2.22M | $-557.81K | $-529.57K | $-493.16K | $496.01K | $-218.22K | $-314.31K |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.94% | 2.85% | 1.59% | -0.39% | 2.95% | 2.65% | 1.00% | -0.68% | -0.51% | -0.96% | 1.00% | -1.50% | -0.33% | 0.95% | 0.91% | 4.40% | 2.36% | -1.30% | 0.32% | 0.74% | 1.00% |
1 analysts predict OPRX's average Quarter EBITDA for Mar 22 to be $-3.29M, with a high of $-2.63M and a low of $-3.95M. This is -426.15% lower than OptimizeRx's previous annual EBITDA (Dec 21) of $1.01M.
OptimizeRx Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Dec 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.87M | $-4.16M | $659.07M | $212.68K | $-3.18M | $-3.86M | $-3.76M | $623.46K | $39.89K | $352.10K | $-637.38K | $1.36M | $-282.89K | $-1.08M | $-2.20M | $-1.98M | $-1.57M | $406.62K | $6.53K | $-189.18K | $-237.06K |
| Avg Forecast | $5.73M | $1.31M | $-197.89K | $-705.64K | $4.54M | $1.08M | $-1.18M | $-6.02M | $7.03M | $458.09K | $-392.65K | $-4.76M | $653.15K | $616.20K | $1.64M | $-3.76M | $3.76M | $2.37M | $1.31M | $-637.38K | $2.83M | $730.32K | $-547.74K | $-2.42M | $91.29K | $1.41M | $1.41M | $20.57K | $-255.39K | $-237.06K |
| High Forecast | $5.93M | $1.36M | $-190.63K | $-640.30K | $5.09M | $1.11M | $-1.14M | $-4.81M | $8.38M | $473.88K | $-378.24K | $-3.81M | $783.78K | $616.20K | $1.64M | $-3.01M | $3.76M | $2.37M | $1.31M | $-509.90K | $2.83M | $730.32K | $-547.74K | $-1.94M | $91.29K | $1.41M | $1.41M | $24.68K | $-204.31K | $-189.65K |
| Low Forecast | $5.52M | $1.26M | $-204.72K | $-770.99K | $4.18M | $1.05M | $-1.22M | $-7.22M | $5.14M | $441.27K | $-406.19K | $-5.71M | $522.52K | $616.20K | $1.64M | $-4.51M | $3.76M | $2.37M | $1.31M | $-764.85K | $2.83M | $730.32K | $-547.74K | $-2.91M | $91.29K | $1.41M | $1.41M | $16.45K | $-306.47K | $-284.47K |
| Surprise % | - | - | - | - | - | - | - | - | - | -6.25% | 10.60% | -138.53% | 0.33% | -5.16% | -2.35% | 1.00% | 0.17% | 0.02% | 0.27% | 1.00% | 0.48% | -0.39% | 1.97% | 0.91% | -21.74% | -1.11% | 0.29% | 0.32% | 0.74% | 1.00% |
OptimizeRx's average Quarter net income forecast for Jun 23 is $-392.65K, with a range of $-406.19K to $-378.24K. OPRX's average Quarter net income forecast represents a -100.06% decrease compared to the company's last Quarter net income of $659.07M (Mar 23).
OptimizeRx SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Dec 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $12.89M | $12.24M | $14.03M | $14.26M | $12.14M | $11.88M | $11.86M | $12.26M | $8.08M | $6.93M | $5.92M | $7.18M | $4.88M | $4.86M | $5.32M | $4.47M | $3.28M | $3.33M | $3.09M | $2.03M | $2.15M |
| Avg Forecast | $22.62M | $16.50M | $14.58M | $14.13M | $19.88M | $16.82M | $13.57M | $17.55M | $18.79M | $10.19M | $9.96M | $8.31M | $12.84M | $10.22M | $11.69M | $10.97M | $13.81M | $10.37M | $8.53M | $5.92M | $10.96M | $6.69M | $5.46M | $5.85M | $5.18M | $4.92M | $4.58M | $3.49M | $2.74M | $2.15M |
| High Forecast | $23.22M | $16.94M | $14.96M | $14.38M | $20.36M | $16.86M | $13.57M | $21.06M | $18.95M | $10.23M | $10.23M | $8.53M | $15.41M | $10.22M | $11.69M | $13.16M | $13.81M | $10.37M | $8.53M | $7.10M | $10.96M | $6.69M | $5.46M | $7.02M | $5.18M | $4.92M | $4.58M | $3.49M | $3.28M | $2.58M |
| Low Forecast | $21.98M | $16.04M | $14.16M | $13.88M | $19.12M | $16.78M | $13.57M | $14.04M | $18.62M | $10.15M | $9.68M | $8.08M | $10.27M | $10.22M | $11.69M | $8.77M | $13.81M | $10.37M | $8.53M | $4.73M | $10.96M | $6.69M | $5.46M | $4.68M | $5.18M | $4.92M | $4.58M | $3.49M | $2.19M | $1.72M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.26% | 1.23% | 1.69% | 1.11% | 1.19% | 1.02% | 1.08% | 0.89% | 0.78% | 0.81% | 1.00% | 0.65% | 0.73% | 0.89% | 0.91% | 0.86% | 0.67% | 0.73% | 0.88% | 0.74% | 1.00% |
OptimizeRx's average Quarter SG&A projection for Dec 23 is $18.79M, based on 3 Wall Street analysts, with a range of $18.62M to $18.95M. The forecast indicates a 45.78% rise compared to OPRX last annual SG&A of $12.89M (Sep 23).
OptimizeRx EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Dec 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 5 | 13 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.17 | $-0.24 | $38.55 | $0.01 | $-0.18 | $-0.21 | $-0.21 | $0.04 | - | $0.02 | $-0.04 | $0.09 | $-0.02 | $-0.07 | $-0.15 | $-0.14 | $-0.11 | $0.03 | - | $-0.02 | $-0.03 |
| Avg Forecast | $0.31 | $0.07 | $-0.01 | $-0.04 | $0.25 | $0.06 | $-0.06 | $-0.13 | $0.38 | $0.03 | $-0.02 | $-0.08 | $0.24 | $0.03 | $0.09 | $-0.01 | $0.21 | $0.13 | $0.07 | $0.01 | $0.15 | $0.04 | $-0.03 | $-0.04 | $0.01 | $0.08 | $0.08 | $0.02 | $-0.08 | $-0.03 |
| High Forecast | $0.32 | $0.07 | $-0.01 | $-0.03 | $0.28 | $0.06 | $-0.06 | $-0.12 | $0.46 | $0.03 | $-0.02 | $-0.08 | $0.25 | $0.03 | $0.09 | $-0.01 | $0.21 | $0.13 | $0.07 | $0.01 | $0.15 | $0.04 | $-0.03 | $-0.04 | $0.01 | $0.08 | $0.08 | $0.02 | $-0.06 | $-0.02 |
| Low Forecast | $0.30 | $0.07 | $-0.01 | $-0.04 | $0.23 | $0.06 | $-0.07 | $-0.13 | $0.28 | $0.02 | $-0.02 | $-0.08 | $0.23 | $0.03 | $0.09 | $-0.01 | $0.21 | $0.13 | $0.07 | $0.01 | $0.15 | $0.04 | $-0.03 | $-0.04 | $0.01 | $0.08 | $0.08 | $0.02 | $-0.10 | $-0.04 |
| Surprise % | - | - | - | - | - | - | - | - | - | -6.80% | 11.20% | -481.87% | 0.05% | -5.33% | -2.33% | 17.50% | 0.17% | 0.02% | 0.28% | -5.00% | 0.58% | -0.50% | 2.33% | 3.75% | -28.00% | -1.42% | 0.39% | 0.02% | 0.24% | 1.00% |
According to 1 Wall Street analysts, OptimizeRx's projected average Quarter EPS for Jun 23 is $-0.02, with a low estimate of $-0.02 and a high estimate of $-0.02. This represents a -100.06% decrease compared to OPRX previous annual EPS of $38.55 (Mar 23).
OptimizeRx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OPRX | OptimizeRx | $5.23 | $15.00 | 186.81% | Buy |
| ACCD | Accolade | $3.40 | $8.08 | 137.65% | Buy |
| FORA | Forian | $2.04 | $4.50 | 120.59% | Buy |
| DH | Definitive Healthcare | $4.46 | $6.08 | 36.32% | Hold |
| CERT | Certara | $11.40 | $15.00 | 31.58% | Buy |
| HQY | HealthEquity | $91.09 | $108.33 | 18.93% | Buy |
| PRVA | Privia Health Group | $20.79 | $23.00 | 10.63% | Buy |
| DOCS | Doximity | $52.70 | $53.38 | 1.29% | Buy |
| HSTM | HealthStream | $31.97 | $29.00 | -9.29% | Buy |